Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 18.09.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 04.03.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | y set forth by specific reference in such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Dire |
| 31.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; C |
| 20.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
Stammdaten
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Unternehmen & Branche
| Name | Passage BIO, Inc. |
|---|---|
| Ticker | PASG |
| CIK | 0001787297 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 17,2 Mio. USD |
| Beta | 1,77 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -45,522,000 | -14.35 | 62,281,000 | 18,755,000 | |
| 2025-09-30 | 10-Q | -7,749,000 | -2.44 | 74,160,000 | 31,120,000 | |
| 2025-06-30 | 10-Q | -9,385,000 | -2.96 | 79,198,000 | 38,258,000 | |
| 2025-03-31 | 10-Q | -15,405,000 | -0.25 | 86,006,000 | 46,706,000 | |
| 2024-12-31 | 10-K | -64,767,000 | -21.04 | 102,412,000 | 61,261,000 | |
| 2024-09-30 | 10-Q | -19,340,000 | -6.15 | 111,752,000 | 72,716,000 | |
| 2024-06-30 | 10-Q | -15,991,000 | -5.09 | 125,392,000 | 90,557,000 | |
| 2024-03-31 | 10-Q | -16,711,000 | -0.30 | 140,531,000 | 104,883,000 | |
| 2023-12-31 | 10-K | -102,062,000 | -1.86 | 150,545,000 | 111,283,000 | |
| 2023-09-30 | 10-Q | -27,110,000 | -0.49 | 169,256,000 | 126,276,000 | |
| 2023-06-30 | 10-Q | -23,856,000 | -0.44 | 193,696,000 | 150,414,000 | |
| 2023-03-31 | 10-Q | -34,338,000 | -0.63 | 213,243,000 | 170,351,000 | |
| 2022-12-31 | 10-K | -136,125,000 | -2.50 | 243,549,000 | 201,366,000 | |
| 2022-09-30 | 10-Q | -26,701,000 | -0.49 | 270,052,000 | 224,396,000 | |
| 2022-06-30 | 10-Q | -39,542,000 | -0.73 | 299,416,000 | 248,046,000 | |
| 2022-03-31 | 10-Q | -42,811,000 | -0.79 | 333,224,000 | 281,311,000 | |
| 2021-12-31 | 10-K | -185,386,000 | -3.48 | 355,076,000 | 318,657,000 | |
| 2021-09-30 | 10-Q | -46,915,000 | -0.87 | 390,941,000 | 362,227,000 | |
| 2021-06-30 | 10-Q | -48,435,000 | -0.90 | 439,525,000 | 402,269,000 | |
| 2021-03-31 | 10-Q | -38,882,000 | -0.76 | 465,172,000 | 441,504,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-01-08 | Borthwick Kathleen | Officer, CFO | Open Market Sale | -2,062 | 18.44 | -38,022.04 | -33,0% | |
| 2026-01-08 | Chou William | Director, Officer, PRESIDENT AND CEO | Open Market Sale | -4,076 | 18.44 | -75,158.99 | -65,2% | |
| 2025-09-15 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 11,900 | 6.99 | 83,175.05 | +72,2% | |
| 2025-09-12 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 19,783 | 6.99 | 138,299.00 | +120,0% | |
| 2025-09-11 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 325 | 6.96 | 2,260.64 | +2,0% | |
| 2025-07-24 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 66,423 | 5.71 | 379,454.67 | +329,2% | |
| 2025-07-23 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 49,302 | 5.74 | 283,032.92 | +245,5% | |
| 2025-07-22 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 13,123 | 5.44 | 71,337.94 | +61,9% | |
| 2025-06-26 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -213,257 | 0.33 | -70,374.81 | -61,1% | |
| 2025-06-25 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -138,800 | 0.33 | -45,804.00 | -39,7% | |
| 2025-06-24 | ORBIMED ADVISORS LLC | 10% Owner | Open Market Sale | -231,600 | 0.35 | -81,060.00 | -70,3% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.